ライフサイエンスコーパス: second-line treatment

1 -related mortality still restrict its use to second line treatment.

2 med RR-TB and those reported to have started second-line treatment.

3 order of hormonal therapies for CRPC beyond second-line treatment.

4 even after adjusting for RFI and response to second-line treatment.

5 to paclitaxel had failed to respond to their second-line treatment.

6 ast cancer, and the other 25% received it as second-line treatment.

7 6 Italian centers, were submitted to ECP for second-line treatment.

8 ternative that is often, but not always, the second-line treatment.

9 ontrolled, phase 3 studies of first-line and second-line treatment.

10 ssion-free survival (PFS) following first or second-line treatment.

11 enefits for trastuzumab emtansine (T-DM1) in second-line treatment.

12 onal outcomes with clozapine positioned as a second-line treatment.

13 sent a reliable tool for predicting OS after second-line treatment.

14 l cancer who may benefit from gefitinib as a second-line treatment.

15 % are refractory to medical therapy and seek second-line treatment.

16 FFS was 56% at 6 months after second-line treatment.

17 e mortality, and recurrent malignancy during second-line treatment.

18 he second year of ART to guide the switch to second-line treatment.

19 rognosis is better than in those who require second-line treatments.

20 outcome after ESA failure and the effect of second-line treatments.

21 rding which patients will benefit from which second-line treatments.

22 is inadequately treated with first-line and second-line treatments.

23 Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received L

24 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation

25 servation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pe

26 ation, lower gastrointestinal involvement at second-line treatment, and severe NIH global score at se

27 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On

28 g the use of mycophenolate and tacrolimus as second-line treatment; and the recent completion of the

29 axane for first-line treatment and T-DM1 for second-line treatment are recommended.

30 However, prognosis and effects of second-line treatment are thus far unknown.

31 Responses to second-line treatment are uncommon.

32 Babies who require second-line treatments are more likely to have hypoxic i

33 se agents are not recommended as a first- or second-line treatment at this time.

34 ntrahepatic portosystemic shunts (TIPS) is a second-line treatment because of an increased incidence

35 Second-line treatments can improve survival and quality

36 t, the notable reduction in response rate to second-line treatments, coupled with clozapine's substan

37 ore effective than either alone and provides second line treatment for those with rhinitis poorly con

38 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus

39 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c

40 renewed enthusiasm for the use of niacin as second-line treatment for atherogenic dyslipidemia, with

41 tinuous positive airway pressure is a useful second-line treatment for children with sleep-disordered

42 y and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinom

43 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.

44 tment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistanc

45 xel, and could be regarded as a new standard second-line treatment for patients with advanced gastric

46 versible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamou

47 rvival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic color

48 cetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric

49 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea

50 ith docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-sma

51 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode

52 considered the staple therapy for gout and a second-line treatment for pericarditis, as well as a bas

53 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

54 nd efficacy of amrubicin versus topotecan as second-line treatment for SCLC.

55 1 phototherapy may be considered a potential second-line treatment for VLS.

56 Identification of more effective second-line treatments for advanced relapsing and refrac

57 that ruxolitinib is not superior to current second-line treatments for ET.

58 unknown primary site (CUP), and no effective second-line treatment has been identified.

59 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro

60 atients are offered URD transplantation as a second-line treatment; however, the impact of pretranspl

61 rognostic factor for treatment failure after second-line treatment (HR, 1.2 per 10 years; 95% CI, 1.2

62 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity

63 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i

64 d pulmonary MDR tuberculosis at the start of second-line treatment in Estonia, Latvia, Peru, Philippi

65 -receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP).

66 The use of gefitinib as a second-line treatment in oesophageal cancer in unselecte

67 Regarding second-line treatment in patients who received first-lin

68 vatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal

69 ty of afatinib compared with methotrexate as second-line treatment in patients with recurrent or meta

70 compared with an ORR of 15% for topotecan as second-line treatment in patients with SCLC sensitive to

71 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ

72 mphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and ste

73 Second-line treatments, including hypomethylating agents

74 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo

75 with steroid-refractory disease, response to second-line treatment is dismal.

76 Radiotherapy can be used as a second-line treatment modality.

77 FFS was defined by the absence of second-line treatment, nonrelapse mortality, and recurre

78 ar on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second ye

79 CPT analogue that was recently approved for second line treatment of colorectal cancer, the 20(S)-gl

80 formulation of an established agent for the second-line treatment of advanced epithelial ovarian can

81 Second-line treatment of advanced NSCLC with pemetrexed

82 placement of splenectomy with rituximab as a second-line treatment of chronic immune thrombocytopenic

83 Although initially restricted to the second-line treatment of ITP, both agents could help tre

84 rinotecan with or without bevacizumab in the second-line treatment of metastatic colorectal cancer.

85 ecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer (NSC

86 can and gemcitabine, with or without CBX, in second-line treatment of NSCLC.

87 Most phase I and II data came from second-line treatment of ovarian cancer, and there have

88 side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC an

89 ingle-agent pemetrexed is safe and active as second-line treatment of patients with advanced TCC of t

90 s active and well tolerated in the first- or second-line treatment of patients with advanced transiti

91 added to systemic therapy in the first- and second-line treatment of patients with colorectal liver

92 only used chemotherapies improved PFS in the second-line treatment of patients with HER2-negative met

93 herapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal g

94 survival when compared with topotecan in the second-line treatment of patients with SCLC.

95 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced

96 ucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.

97 r PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

98 have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers.

99 on (AF) has emerged as a widespread first or second line treatment option.

100 These results establish axitinib as a second-line treatment option for patients with metastati

101 A second-line treatment option is azathioprine, but effica

102 Few standard second-line treatment options exist for advanced sarcoma

103 ocarcinoma have a poor prognosis and limited second-line treatment options.

104 in the post-implementation group initiated a second-line treatment regimen more rapidly than those in

105 n of the market for drugs for first-line and second-line treatment regimens, having supplied, for exa

106 ll consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

107 an additional option in the postadjuvant or second-line treatment setting for patients who experienc

108 -line therapies, there is an urgent need for second-line treatment strategies for pediatric patients

109 ding could have significant implications for second-line treatment strategies in this clinical settin

110 Second-line treatment strategies included intensified sa

111 icosteroids followed by various conventional second-line treatments such as methotrexate and azathiop

112 By combining screening with second-line treatments targeting innate insensitivity, u

113 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b

114 t efficacy.If the first-line therapy fails a second-line treatment using tetracycline, furazolidone a

115 improved OS was associated with response to second-line treatment versus no response (46% v 0%, resp

116 We observed that splenectomy for ITP second-line treatment was more effective than Rituximab

117 Second-line treatment was predefined (FOLFIRI for the EC

118 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec

119 ne treatment, and severe NIH global score at second-line treatment were associated with increased ris

120 ome of 119 patients who received a 2G-TKI as second-line treatment while still in the chronic phase.

121 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie

122 Second-line treatment with chemotherapy is generally res

123 patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatm

124 Second-line treatment with ramucirumab did not significa

125 Second-line treatment with rituximab leads to response r

126 ) achieved a partial or complete response to second-line treatment, with a median duration of respons